Cirio advises Annexin Pharmaceuticals AB (publ) in connection with its fully secured rights issue
Cirio advises Annexin Pharmaceuticals AB (publ) (”Annexin”) in connection with its fully secured rights issue of shares. The rights issue is subject to subsequent approval by an Extraordinary General Meeting, to be held on 24 November 2023.
Annexin is a leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company’s biological drug candidate ANXV is primarily intended for the treatment of patients with vascular injuries and inflammation, but also for cancer. The company’s share is listed on Nasdaq First North Growth Market.
Cirio advised Annexin Pharmaceuticals AB (publ) with a team headed by Maria Arnoldsson (Equity Capital Markets and Public M&A) and Per Hedman (Life sciences), together with Louise Åberg and Rikard Kåresen (Equity Capital Markets and Public M&A).
For more information, please contact:
Ursäkta, vi kunde inte hitta några inlägg. Försök med en annan sökning.